长链非编码RNA PANDAR调节胶质瘤细胞的增殖和上皮-间质转化。
The long non-coding RNA PANDAR regulates cell proliferation and epithelial-to-mesenchymal transition in glioma.
作者信息
Guo Jianfeng, Xiao Deyong, Lin Zhijing, Sui Chengzhi
机构信息
Department of Neurosurgy, The First Affiliated Hospital of Xiamen University, Xiamen, China.
Department of Rehabilitation, The First Affiliated Hospital of Xiamen University, Xiamen, China.
出版信息
Histol Histopathol. 2023 Feb;38(2):199-208. doi: 10.14670/HH-18-511. Epub 2022 Sep 8.
Glioma is one of the most aggressive intracranial tumors in the central nervous system. The long non-coding RNA P21 associated ncRNA DNA damage activated (PANDAR) has been reported to be an oncogene or tumor suppressor in several cancers. However, the prognostic value and biological function of PANDAR in glioma have not been described. Here, we report that expression of PANDAR is significantly up-regulated in glioma tissues and cell lines. PANDAR expression was correlated with tumor size (p=0.044) and World Health Organization (WHO) grades (p=0.005), as shown by chi-squared test. Moreover, significant upregulation of PANDAR was found to correlate with poor prognosis in glioma, as shown using Kaplan-Meier method and Cox multivariate survival analysis. Furthermore, PANDAR knockdown suppressed cell proliferation, G1/S transition, migration and invasion, and promoted apoptosis in glioma cell lines (U251 and U87). PANDAR knockdown decreased expression of CDK4, Bcl-2, N-cadherin and Vimentin, but increased E-cadherin expression in glioma cells. In conclusion, our data suggest PANDAR as a potential prognostic biomarker and therapeutic candidate for glioma.
胶质瘤是中枢神经系统中最具侵袭性的颅内肿瘤之一。据报道,长链非编码RNA P21相关ncRNA DNA损伤激活因子(PANDAR)在几种癌症中是一种癌基因或肿瘤抑制因子。然而,PANDAR在胶质瘤中的预后价值和生物学功能尚未见报道。在此,我们报告PANDAR在胶质瘤组织和细胞系中的表达显著上调。卡方检验显示,PANDAR表达与肿瘤大小(p = 0.044)和世界卫生组织(WHO)分级(p = 0.005)相关。此外,使用Kaplan-Meier方法和Cox多因素生存分析表明,PANDAR的显著上调与胶质瘤的不良预后相关。此外,敲低PANDAR可抑制胶质瘤细胞系(U251和U87)的细胞增殖、G1/S期转换、迁移和侵袭,并促进细胞凋亡。敲低PANDAR可降低胶质瘤细胞中CDK4、Bcl-2、N-钙黏蛋白和波形蛋白的表达,但增加E-钙黏蛋白的表达。总之,我们的数据表明PANDAR是胶质瘤潜在的预后生物标志物和治疗靶点。